BIIB
BiogenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull read is that Q1 showed better-than-feared core execution: revenue and EPS grew year over year, growth products remained strong, LEQEMBI sales kept scaling, and management framed Apellis plus felzartamab as portfolio actions that can improve the medium-term growth mix. The dated May 24 LEQEMBI IQLIK decision adds a near-term regulatory hook.
Posture
Constructive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-06-03.
What can break
2026 non-GAAP EPS guidance was cut to $14.25-$15.25 from $15.25-$16.25, excluding Apellis, due to acquired IPR&D charges tied to business-development activity, with about $0.80 of the impact expected in Q2. [#8-K-2026-04-29]
Momentum
63
Value
68
Sentiment
54
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $203.00 · Bull $220.00 · Bear $170.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $209.19
Why
Momentum63 · Δ7d -6.8
Value68 · Δ7d +0.3
Sentiment54 · Δ7d +4.2
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
63
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.8
Δ21d
-1.2
Value
68
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.7
Sentiment
54
33% active weight
Current posture
7d trendImproving
Δ7d
+4.2
Δ21d
+10.9
Why this grade
Composite grade B. Momentum 63.5 / Value 68.3 / Sentiment 54.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$27.88B
Beta
0.16
Shares Out
146.7M
P/E (TTM)
15.9
P/S (TTM)
2.55
P/FCF (TTM)
11.33
Rev YoY
+2.8%
EPS YoY
+19.3%
Gross Margin
+75.2%
Op Margin
+21.9%
Net Debt
$3.92B
Current Ratio
2.72
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology